BACKGROUND: A human immunodeficiency virus (HIV) vaccine that limits disease and transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an HIV vaccine that combines a plasmid-DNA priming vaccine and a modified vaccinia virus Ankara (MVA) boosting vaccine. METHODS:Forty healthy volunteers were injected with DNA plasmids containing gp160 of HIV-1 subtypes A, B, and C; rev B; p17/p24 gag A and B, and RTmut B by use of a needle-free injection system. The vaccine was administered intradermally or intramuscularly, with or without recombinant granulocyte macrophage colony-stimulating factor, and boosted with a heterologous MVA containing env, gag, and pol of CRF01A_E. Immune responses were monitored with HIV-specific interferon (IFN)-gamma and interleukin (IL)-2 ELISpot and lymphoproliferative assays (LPAs). RESULTS:Vaccine-related adverse events were mild and tolerable. After receipt of the DNA priming vaccine, 11 (30%) of 37 vaccinees had HIV-specific IFN-gamma responses. After receipt of the MVA boosting vaccine, ELISpot assays showed that 34 (92%) of 37 vaccinees had HIV-specific IFN-gamma responses, 32 (86%) to Gag and 24 (65%) to Env. IFN-gamma production was detected in both the CD8(+) T cell compartment (5 of 9 selected vaccinees) and the CD4(+) T cell compartment (9 of 9). ELISpot results showed that 25 (68%) of 37 vaccinees had a positive IL-2 response and 35 (92%) of 38 had a positive LPA response. Of 38 subjects, a total of 37 (97%) were responders. One milligram of HIV-1 DNA administered intradermally was as effective as 4 mg administered intramuscularly in priming for the MVA boosting vaccine. CONCLUSION: This HIV-DNA priming-MVA boosting approach is safe and highly immunogenic. TRIALS REGISTRATION: International Standard Randomised Controlled Trial number: ISRCTN32604572 .
RCT Entities:
BACKGROUND: A human immunodeficiency virus (HIV) vaccine that limits disease and transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an HIV vaccine that combines a plasmid-DNA priming vaccine and a modified vaccinia virus Ankara (MVA) boosting vaccine. METHODS: Forty healthy volunteers were injected with DNA plasmids containing gp160 of HIV-1 subtypes A, B, and C; rev B; p17/p24gag A and B, and RTmut B by use of a needle-free injection system. The vaccine was administered intradermally or intramuscularly, with or without recombinant granulocyte macrophage colony-stimulating factor, and boosted with a heterologous MVA containing env, gag, and pol of CRF01A_E. Immune responses were monitored with HIV-specific interferon (IFN)-gamma and interleukin (IL)-2 ELISpot and lymphoproliferative assays (LPAs). RESULTS: Vaccine-related adverse events were mild and tolerable. After receipt of the DNA priming vaccine, 11 (30%) of 37 vaccinees had HIV-specific IFN-gamma responses. After receipt of the MVA boosting vaccine, ELISpot assays showed that 34 (92%) of 37 vaccinees had HIV-specific IFN-gamma responses, 32 (86%) to Gag and 24 (65%) to Env. IFN-gamma production was detected in both the CD8(+) T cell compartment (5 of 9 selected vaccinees) and the CD4(+) T cell compartment (9 of 9). ELISpot results showed that 25 (68%) of 37 vaccinees had a positive IL-2 response and 35 (92%) of 38 had a positive LPA response. Of 38 subjects, a total of 37 (97%) were responders. One milligram of HIV-1 DNA administered intradermally was as effective as 4 mg administered intramuscularly in priming for the MVA boosting vaccine. CONCLUSION: This HIV-DNA priming-MVA boosting approach is safe and highly immunogenic. TRIALS REGISTRATION: International Standard Randomised Controlled Trial number: ISRCTN32604572 .
Authors: R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson Journal: Science Date: 2001-04-06 Impact factor: 47.728
Authors: Andrew T Catanzaro; Mario Roederer; Richard A Koup; Robert T Bailer; Mary E Enama; Martha C Nason; Julie E Martin; Steve Rucker; Charla A Andrews; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham Journal: Vaccine Date: 2007-03-07 Impact factor: 3.641
Authors: Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael Journal: J Virol Date: 2006-05 Impact factor: 5.103
Authors: Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham Journal: J Infect Dis Date: 2006-11-08 Impact factor: 5.226
Authors: Andreas Bråve; Andreas Boberg; Lindvi Gudmundsdotter; Erik Rollman; Kristian Hallermalm; Karl Ljungberg; Pontus Blomberg; Richard Stout; Staffan Paulie; Eric Sandström; Gunnel Biberfeld; Patricia Earl; Bernard Moss; Josephine H Cox; Britta Wahren Journal: Mol Ther Date: 2007-06-19 Impact factor: 11.454
Authors: B Mäkitalo; P Lundholm; J Hinkula; C Nilsson; K Karlén; A Mörner; G Sutter; V Erfle; J L Heeney; B Wahren; G Biberfeld; R Thorstensson Journal: J Gen Virol Date: 2004-08 Impact factor: 3.891
Authors: Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban Journal: J Virol Date: 2010-06-09 Impact factor: 5.103
Authors: Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström Journal: J Virol Date: 2012-02-08 Impact factor: 5.103
Authors: Paul A Goepfert; Marnie L Elizaga; Alicia Sato; Li Qin; Massimo Cardinali; Christine M Hay; John Hural; Stephen C DeRosa; Olivier D DeFawe; Georgia D Tomaras; David C Montefiori; Yongxian Xu; Lilin Lai; Spyros A Kalams; Lindsey R Baden; Sharon E Frey; William A Blattner; Linda S Wyatt; Bernard Moss; Harriet L Robinson Journal: J Infect Dis Date: 2011-01-31 Impact factor: 5.226
Authors: David Hallengärd; B Kristian Haller; Anna-Karin Maltais; Eva Gelius; Kopek Nihlmark; Britta Wahren; Andreas Bråve Journal: Clin Vaccine Immunol Date: 2011-07-13
Authors: Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher Journal: J Virol Date: 2009-01-28 Impact factor: 5.103
Authors: Charlotta Nilsson; Karina Godoy-Ramirez; Bo Hejdeman; Andreas Bråve; Lindvi Gudmundsdotter; David Hallengärd; Jeffrey R Currier; Lindsay Wieczorek; Klara Hasselrot; Patricia L Earl; Victoria R Polonis; Mary A Marovich; Merlin L Robb; Eric Sandström; Britta Wahren; Gunnel Biberfeld Journal: AIDS Res Hum Retroviruses Date: 2013-11-15 Impact factor: 2.205